For any attendee who may be new to the large conference, Dr. Vonderheide encouraged stopping in at each day’s plenary session and staying to listen to every talk. “At first glance, the meeting can feel overwhelming, but the plenary sessions have something for every expert and there are n...
This year, the theme of the American Association for Cancer Research (AACR) conference that held from the 16th to the 20th of April 2016 was "Delivering Cures through Cancer Science". Its objective was to reinforce the link existing between research and advances in patient's care. As usual,...
Title: The potential of multi-cancer early detection screening for reducing cancer mortality Oral presentation:Friday, November 15, 9:35 a.m. PT (Plenary Session 4: Early Detection of Primary Cancer and Relapse) Presenter:Tyson, C Poster number:PR006, A073 K...
During his Plenary Session presentation, "From genes to microenvironments: cancer as an 'organismal' disease," Siddhartha Mukherjee (Columbia University, NY) outlined how our view of cancer has shifted over time. It was originally thought to be a disease of cells, but advances in ...
today announced the presentation of additional data from its ongoing Phase 1 open-label, dose-escalation trial of PRT3789, a first-in-class, highly selective SMARCA2 degrader designed to treat cancer patients with a SMARCA4 mutation. The data were presented at a plenary session of the 36thAnnual...
In our latest postcard from AACR20 virtual meeting we take a look at the adoptive cell therapy plenary session April 28, 2020 E Postcards from Day 1 of AACR20 Commentary on Day 1 of the AACR20 Virtual Meeting April 28, 2020 E One swallow does not a summer make Why you should ...
The conference was co-chaired by Charles L. Sawyers form Memorial Sloan Kettering Cancer Center in New York, Elaine R. Mardis form Washington University School of Medicine in St. Louis, and Arul M. Chinnaiyan from University of Michigan in Ann Arbor. About 500 clinicians, basic science ...
In the many plenary sessions a vision came together of a future when a patient's cancer will be characterized with one of many available "omics" platforms (e.g. whole genome sequencing, epigenomics, proteomics, and metabolomics) to identify a targetable lesion within the tumor, such that ...